News Network


Screening and Treatment for Lung Cancer: What's Next?

October 13th 2021

The second part of the webinar Lung Cancer Screening and Treatment: What's Next? focuses on the review of lung cancer screening and treatment status amid the COVID-19 pandemic. Participating faculty include Albert Rizzo, MD, FCCP, FACP, FAASM; James L. Mulshine, MD; Andrea Borondy Kitts, MS, MPH; and Sandip Patel, MD.

New Treatment Options in Chronic GVHD

October 8th 2021

An expert hematologist/oncologist will highlight the traditional treatment options, unmet needs, and recent advances and approvals in chronic graft vs host disease. Clinical trials will be described as well as novel agents on the horizon.

Updates in CLL: A Closer Look at Adverse Events

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, discuss adverse events associated with treating chronic lymphocytic leukemia, particularly when utilizing BTK inhibitors.

Update from HER2CLIMB in Relapsed Refractory HER2-Positive Breast Cancer

September 8th 2021

Implications for treating patients with progressive, unresectable locally advanced or metastatic HER2-positive breast cancer with tucatinib in combination with capecitabine and trastuzumab.

Post-Conference Perspectives: Chronic Lymphocytic Leukemia

August 16th 2021

Experts share their perspective on the optimal management of chronic lymphocytic leukemia in light of recent clinical data for novel targeted therapies.

Rare Drivers in Metastatic Non-Small-Cell Lung Cancer with a Focus on EGFR Exon 20 Insertion Mutations

July 28th 2021

Expert thoracic oncologists discuss the importance of comprehensive molecular testing and optimal use of novel targeted agents in metastatic non-small cell lung cancer.

Post-Conference Perspectives: Myeloproliferative Neoplasms

July 28th 2021

Key opinion leaders in the treatment of myeloproliferative neoplasms, Pankit Vachhani, MD, and Jamile Shammo, MD, share expert perspectives on ruxolitinib for patients with primary myelofibrosis and polycythemia vera.

Advanced Prostate Cancer: PSMA-Targeted Radioligand Therapies

July 23rd 2021

PSMA-Targeted Radioligand Therapies in Advanced Prostate Cancer

July 23rd 2021

The rationale behind the use of lutetium-177-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

The Evolving Role of NGS and Germline Sequencing in Patients with Advanced and Metastatic Cancer

July 22nd 2021

Experts discuss recent data on next generation sequencing and germline testing in patients with advanced and metastatic cancer.

Uveal Melanoma

July 20th 2021

Drs Richard D. Carvajal and Marlana M. Orloff describe the rationale for treating uveal melanoma with tebentafusp and provide insight on assessing treatment response and managing treatment-related adverse events.

Tipifarnib in HRAS-mutant Head and Neck Squamous Cell Carcinoma

July 19th 2021

Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.

Tucatinib in Combination with Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer

July 15th 2021

Sara A. Hurvitz, MD, discusses updated results of the HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer.

Antibody-Drug Conjugates in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

July 13th 2021

Best practices when prescribing and managing antibody-drug conjugate therapy as treatment for relapsed/refractory diffuse large B-cell lymphoma.

Post-Conference Perspectives: Hormone Receptor-Positive Advanced Breast Cancer

July 9th 2021

Nicholas McAndrew, MD, MSCE provides his perspective on how findings reported at ASCO 2021 will impact treatment of patients with PIK3CA-mutated HR+, HER2- advanced breast cancer. In this series, Dr. McAndrew reviews the overall survival results from MONALEESA-3, the joint analysis of SOLAR-1 and X2101, the design and outcomes of the BYLieve trial, and real-world clinical outcomes using alpelisib in patients with PIK3CA-mutated HR+, HER2- advanced breast cancer.

After COVID-19: Lung Cancer Screening and Treatment

July 8th 2021

This expert panel focuses in on the significance of lung cancer screening and treatment approaches following the COVID-19 pandemic.

ZUMA-3: CAR T Therapy for Adult Patients With ALL

June 30th 2021

Key opinion leaders in hematology oncology, Eunice Wang, MD and Bijal Shah, MD, MS, review the results of the ZUMA trial of CAR T cell therapy in adult patients with relapsed/refractory ALL. 

OncLive News Network: On Location at ASCO 2021

May 25th 2021

Join us LIVE at this year's virtual 2021 ASCO Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic malignancies, and hematologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.


Post-Conference Perspectives: RxPONDER, SABCS 2020

May 7th 2021

Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, discuss the practice-changing results and real-world implications of the RxPONDER trial for patients with HR+ HER2- breast cancer.

Post Conference Perspectives: Trilaciclib, a New Option for Chemotherapy-Induced Myelosuppression

May 6th 2021

Ralph Boccia, MD and Jim Schwartz, RPh provide key insights into the recent FDA approval of trilaciclib and discuss its impact on the treatment landscape for extensive-stage small cell lung cancer.